Translational Breast Cancer Research Consortium 022: Pre- and Post-operative Neratinib for HER2-positive Breast Cancer Brain Metastases

Translational Breast Cancer Research Consortium 022: Pre- and Post-operative Neratinib for HER2-positive Breast Cancer Brain Metastases

We examined neratinib administration pre- and post-operatively in 5 patients with HER2-positive brain metastases. Two patients remained on therapy for 13 cycles and nearly 6 years postoperatively. We observed low CSF drug levels and variable craniotomy specimen levels among evaluable specimens. Incl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical breast cancer 2019-08, Vol.20 (2), p.145-151.e2
Hauptverfasser: Freedman, Rachel A., Gelman, Rebecca S., Agar, Nathalie Y. R., Santagata, Sandro, Randall, Elizabeth C., Gimenez-Cassina Lopez, Begoña, Connolly, Roisin M., Dunn, Ian F., Van Poznak, Catherine H., Anders, Carey K., Melisko, Michelle E., Silvestri, Kelly, Cotter, Christine M., Componeschi, Kathryn P., Marte, Juan M., Moy, Beverly, Blackwell, Kimberly L., Puhalla, Shannon L., Ibrahim, Nuhad, Moynihan, Timothy J., Nangia, Julie, Tung, Nadine, Burns, Robyn, Rimawi, Mothaffar F., Krop, Ian E., Wolff, Antonio C., Winer, Eric P., Lin, Nancy U.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We examined neratinib administration pre- and post-operatively in 5 patients with HER2-positive brain metastases. Two patients remained on therapy for 13 cycles and nearly 6 years postoperatively. We observed low CSF drug levels and variable craniotomy specimen levels among evaluable specimens. Inclusion of novel correlative analyses will continue to be crucial in advancing our understanding of CNS drug penetration.
ISSN:1526-8209
1938-0666
DOI:10.1016/j.clbc.2019.07.011